Search

Displaying results 2011 - 2020 of 8412 in total
  1. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

  2. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam a...

  3. Drug

    Amibegron

    go.drugbank.com/drugs/DB05395
    Investigational

    Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.

  4. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion … [A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inducers
  5. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.

  6. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.

  7. Drug

    Methohexital

    go.drugbank.com/drugs/DB00474
    Approved

    An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.

    Synonyms: α-DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
  8. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the … Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache

    Mixtures: HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/ml, HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/mlCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  10. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein [A31551]. … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as

    Products: Xyntha 250 IU Powder and Solvent for Solution for Injection, Xyntha 1000 IU Powder and Solvent for Solution for Injection